Samuel Bral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samuel Bral has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Guy Storme
Department of Radiation Oncology, Oncology Center, Universitair Ziekenhuis Brussel (UZB), Brussels, Belgium
5 shared publicationsDenis Schallier
Department of Medical Oncology, Oncology Center, Universitair Ziekenhuis Brussel (UZB), Brussels, Belgium
3 shared publicationsHendrik Everaert
Department of Nuclear Medicine, Oncology Center, Brussels University Hospital, Brussels, Belgium
3 shared publicationsKoen Tournel
Department of Radiation Oncology, Oncology Center, Universitair Ziekenhuis Brussel (UZB), Brussels, Belgium
3 shared publications- Mark De Ridder
Department of Radiotherapy, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
3 shared publications Michaël Duchateau
Department of Radiation Oncology, Oncology Center, Universitair Ziekenhuis Brussel (UZB), Brussels, Belgium
3 shared publications
Latest Publications
- Open Access
- 7 January 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 77 (5) , 1352-1359
Toxicity and Outcome Results of a Class Solution With Moderately Hypofractionated Radiotherapy in Inoperable Stage III Non–Small Cell Lung Cancer Using Helical Tomotherapy
- 7 January 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 77 (5) , 1352-1359
Open AccessToxicity and Outcome Results of a Class Solution With Moderately Hypofractionated Radiotherapy in Inoperable Stage III Non–Small Cell Lung Cancer Using Helical Tomotherapy
- Open Access
Toxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy
BACKGROUND: The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system).METHODS: This phase 1/2 study was designed to determine the maximum tolerated dose (MTD) of radiotherapy in patients with LANSCLC administered concurrently with docetaxel and cisplatin. Radiotherapy was delivered using HT. A dose per fraction escalation was applied starting at 2 grays (Gy), with an increase of 6% per dose cohort (DC). The Radiation Therapy Oncology Group acute radiation morbidity score was used to monitor pulmonary, esophageal, and cardiac toxicity.RESULTS: Dose escalation was performed in 34 patients over 5 DCs to a dose per fraction of 2.48 Gy. No differences were observed in acute toxicity between the different DCs. However, a significant increase in late lung toxicity in DC IV, which received a fraction size of 2.36 Gy, necessitated a halt in further dose escalation with the MTD defined as 2.24 Gy per fraction. The overall incidence of acute grade ≥3 esophageal and pulmonary toxicity was 24% and 3%, respectively (grading determined according to the Radiation Therapy Oncology Group‐European Organisation for Research and Treatment of Cancer toxicity scoring system). The overall incidence of late lung toxicity was 21%, but the incidence was an acceptable 13% in DCs I, II, and III. The local response rate was 61% on computed tomography images.CONCLUSIONS: The use of HT to 67.2 Gy with concurrent cisplatin/docetaxel was feasible and resulted in acceptable toxicity. A full phase 2 study has been initiated to establish the true local response rate at the MTD of 2.24 Gy per fraction. Cancer 2010. © 2010 American Cancer Society.
Open AccessToxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy
BACKGROUND: The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system).METHODS: This phase 1/2 study was designed to determine the maximum tolerated dose (MTD) of radiotherapy in patients with LANSCLC administered concurrently with docetaxel and cisplatin. Radiotherapy was delivered using HT. A dose per fraction escalation was applied starting at 2 grays (Gy), with an increase of 6% per dose cohort (DC). The Radiation Therapy Oncology Group acute radiation morbidity score was used to monitor pulmonary, esophageal, and cardiac toxicity.RESULTS: Dose escalation was performed in 34 patients over 5 DCs to a dose per fraction of 2.48 Gy. No differences were observed in acute toxicity between the different DCs. However, a significant increase in late lung toxicity in DC IV, which received a fraction size of 2.36 Gy, necessitated a halt in further dose escalation with the MTD defined as 2.24 Gy per fraction. The overall incidence of acute grade ≥3 esophageal and pulmonary toxicity was 24% and 3%, respectively (grading determined according to the Radiation Therapy Oncology Group‐European Organisation for Research and Treatment of Cancer toxicity scoring system). The overall incidence of late lung toxicity was 21%, but the incidence was an acceptable 13% in DCs I, II, and III. The local response rate was 61% on computed tomography images.CONCLUSIONS: The use of HT to 67.2 Gy with concurrent cisplatin/docetaxel was feasible and resulted in acceptable toxicity. A full phase 2 study has been initiated to establish the true local response rate at the MTD of 2.24 Gy per fraction. Cancer 2010. © 2010 American Cancer Society.
- 1 June 2009
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 91 (3) , 438-442
Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC
- 1 June 2009
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 91 (3) , 438-442
Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC
- 1 February 2008
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 184 (2) , 100-104
The Use of Molecular Imaging to Evaluate Radiation Fields in the Adjuvant Setting of Breast Cancer
- 1 February 2008
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 184 (2) , 100-104
The Use of Molecular Imaging to Evaluate Radiation Fields in the Adjuvant Setting of Breast Cancer
- 28 August 2007
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 84 (3) , 252-256
A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer
- 28 August 2007
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 84 (3) , 252-256
A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer